Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nehad M Ayoub, Kamal M Al-Shami, Mohammad A Alqudah & Nizar M Mhaidat. (2017) Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. OncoTargets and Therapy 10, pages 4869-4883.
Read now
Read now
Manuela Gambella, Antonio Palumbo & Alberto Rocci. (2015) MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?. Expert Review of Molecular Diagnostics 15:7, pages 881-893.
Read now
Read now
Articles from other publishers (19)
Yan Yu, Xiao-Dan Peng, Xiao-Jun Qian, Kai-Ming Zhang, Xiang Huang, Yu-Hong Chen, Yun-Tian Li, Gong-Kan Feng, Hai-Liang Zhang, Xue-Lian Xu, Shun Li, Xuan Li, Jia Mai, Zhi-Ling Li, Yun Huang, Dong Yang, Li-Huan Zhou, Zhuo-Yan Zhong, Jun-Dong Li, Rong Deng & Xiao-Feng Zhu. (2021) Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Negin Taghehchian, Meysam Moghbeli, Baratali Mashkani & Mohammad Reza Abbaszadegan. (2021) The Level of Mesenchymal-Epithelial Transition Autophosphorylation is Correlated with Esophageal Squamous Cell Carcinoma Migration. Iranian Biomedical Journal 25:4, pages 243-254.
Crossref
Crossref
Amr K.A. Bass, Mona S. El-Zoghbi, El-Shimaa M. Nageeb, Mamdouh F.A. Mohamed, Mohamed Badr & Gamal El-Din A. Abuo-Rahma. (2021) Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. European Journal of Medicinal Chemistry 209, pages 112904.
Crossref
Crossref
Mesfer Al Shahrani, Meenakshisundaram Balasubramaniam, Mohammad Y. Alshahrani, Ahmed Saif, Ayed A. Dera, Sultan Alasmari, Mohammad Abohassan, Mohammed Makkawi, Suresh Radhakrishnan & Prasanna Rajagopalan. (2020) Computational and in vitro characterization of ICY‐5: A potential candidate promoting mitochondrial apoptosis via the c‐MET and STAT3 pathways. Journal of Cellular Physiology 236:1, pages 146-156.
Crossref
Crossref
Emmanuel Bresso, Alessandro Furlan, Philippe Noel, Vincent Leroux, Flavio Maina, Rosanna Dono & Bernard Maigret. (2020) Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. Molecules 25:4, pages 938.
Crossref
Crossref
Yifeng Yang, Yingxiu Li, Yunlei Hou, Mingze Qin, Ping Gong, Ju Liu & Yanfang Zhao. (2019) Design, synthesis, and biological evaluation of 4-phenoxyquinoline derivatives as potent c-Met kinase inhibitor. Bioorganic & Medicinal Chemistry Letters 29:23, pages 126666.
Crossref
Crossref
Yi Gu, Yang Sai, Jian Wang, Meijing Yu, Guanglin Wang, Li Zhang, Hongcan Ren, Shiming Fan, Yongxin Ren, Weiguo Qing & Weiguo Su. (2019) Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. European Journal of Pharmaceutical Sciences 136, pages 104938.
Crossref
Crossref
Yepeng Luan, Jerry Li, Jean A. Bernatchez & Rongshi Li. (2018) Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry 62:7, pages 3171-3183.
Crossref
Crossref
Karyn Muzinga Ndolo, Su Jin An, Kyeong Ryang Park, Hyo Jeong Lee, Kyoung Bin Yoon, Yong-Chul Kim & Sun-Young Han. (2019)
Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with
In Vitro
Anti-Tumor Effects
. Biomolecules & Therapeutics 27:2, pages 216-221.
Crossref
Crossref
Palak K. Parikh & Manjunath D. Ghate. (2018) Recent advances in the discovery of small molecule c-Met Kinase inhibitors. European Journal of Medicinal Chemistry 143, pages 1103-1138.
Crossref
Crossref
James I. Geller, John P. Perentesis, Xiaowei Liu, Charles G. Minard, Rachel A. Kudgus, Joel M. Reid, Elizabeth Fox, Susan M. Blaney & Brenda J. Weigel. (2017) A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood & Cancer 64:11, pages e26565.
Crossref
Crossref
Estelle Daudigeos-Dubus, Ludivine Le Dret, Olivia Bawa, Paule Opolon, Albane Vievard, Irène Villa, Jacques Bosq, Gilles Vassal & Birgit Geoerger. (2017) Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. International Journal of Oncology 50:1, pages 203-211.
Crossref
Crossref
Junjun Zhao, Lei Fang, Xiaobing Zhang, Yan Liang & Shaohua Gou. (2016) Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors. Bioorganic & Medicinal Chemistry 24:16, pages 3483-3493.
Crossref
Crossref
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming-Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer & Penelope Bradbury. (2016) Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment 157:1, pages 109-116.
Crossref
Crossref
Na Liu, Yanfen Wang, Gongchao Huang, Conghui Ji, Wei Fan, Haitao Li, Ying Cheng & Hongqi Tian. (2016) Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors. Bioorganic Chemistry 65, pages 146-158.
Crossref
Crossref
Xiao-De An, Hongyan Liu, Zhong-Liang Xu, Yi Jin, Xia Peng, Ying-Ming Yao, Meiyu Geng & Ya-Qiu Long. (2015) Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization. Bioorganic & Medicinal Chemistry Letters 25:3, pages 708-716.
Crossref
Crossref
Xiaolong Jiang, Hongyan Liu, Zilan Song, Xia Peng, Yinchun Ji, Qizheng Yao, Meiyu Geng, Jing Ai & Ao Zhang. (2015) Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold. Bioorganic & Medicinal Chemistry 23:3, pages 564-578.
Crossref
Crossref
Jia-Ru Wu, Chi-Tan Hu, Ren-In You, Pei-Ling Ma, Siou-Mei Pan, Ming-Che Lee & Wen-Sheng Wu. (2015) Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways. PLOS ONE 10:1, pages e0114495.
Crossref
Crossref
Hisato Kawakami, Isamu Okamoto, Wataru Okamoto, Junko Tanizaki, Kazuhiko Nakagawa & Kazuto Nishio. (2014) Targeting MET Amplification as a New Oncogenic Driver. Cancers 6:3, pages 1540-1552.
Crossref
Crossref